

Figure S1. Additional human data. CAFs and NFs were obtained from Patient 1 and Patient 2. (A) Fibroblasts from Patient 1 were untreated, or treated with 10 μ M or 30 μ M EPA. (B) Fibroblasts from Patient 2 were untreated or treated with 30 μ M EPA. The cell viability of all fibroblasts were assessed with the WST-1 assay. (C-F) CAFs and NFs from Patient 1 and Patient 2 were untreated, treated with 30 μ M EPA, treated with 50 μ g/ml LPS or treated with 30 μ M EPA and 50 μ g/ml LPS. The concentration of IL-6 secreted from CAFs and NFs from (C) Patient 1 and (D) Patient 2. The concentration of VEGF secreted from CAFs from (E) Patient 1 and (F) Patient 2. Data are representative of three independent experiments and are presented as mean \pm standard error of the mean. CTL, control; IL, interleukin; VEGF, vascular endothelial growth factor; CAF, cancer-associated fibroblast; NF, normal fibroblast; EPA, eicosapentaenoic acid; LPS, lipopolysaccharide.

